BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16257560)

  • 1. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies.
    Krohn K; Stanescu I; Blazevic V; Vesikari T; Ranki A; Ustav M
    Microbes Infect; 2005 Nov; 7(14):1405-13. PubMed ID: 16257560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
    Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
    Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
    Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rationale behind a vaccine based on multiple HIV antigens.
    Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
    Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes.
    Hinkula J; Svanholm C; Schwartz S; Lundholm P; Brytting M; Engström G; Benthin R; Glaser H; Sutter G; Kohleisen B; Erfle V; Okuda K; Wigzell H; Wahren B
    J Virol; 1997 Jul; 71(7):5528-39. PubMed ID: 9188627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criteria for selection of HIV vaccine candidates--general principles.
    Ensoli B
    Microbes Infect; 2005 Nov; 7(14):1433-5. PubMed ID: 16213181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.
    Rolland M; Jensen MA; Nickle DC; Yan J; Learn GH; Heath L; Weiner D; Mullins JI
    J Virol; 2007 Aug; 81(16):8507-14. PubMed ID: 17537854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.
    Fischer W; Perkins S; Theiler J; Bhattacharya T; Yusim K; Funkhouser R; Kuiken C; Haynes B; Letvin NL; Walker BD; Hahn BH; Korber BT
    Nat Med; 2007 Jan; 13(1):100-6. PubMed ID: 17187074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.
    Xin KQ; Urabe M; Yang J; Nomiyama K; Mizukami H; Hamajima K; Nomiyama H; Saito T; Imai M; Monahan J; Okuda K; Ozawa K; Okuda K
    Hum Gene Ther; 2001 Jun; 12(9):1047-61. PubMed ID: 11399227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
    Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost.
    Billaut-Mulot O; Idziorek T; Loyens M; Capron A; Bahr GM
    Vaccine; 2001 Apr; 19(20-22):2803-11. PubMed ID: 11282190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates.
    Wang B; Boyer J; Srikantan V; Coney L; Carrano R; Phan C; Merva M; Dang K; Agadjanan M; Gilbert L
    DNA Cell Biol; 1993 Nov; 12(9):799-805. PubMed ID: 8216851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines based on Nef and on Nef/DeltaV2 Env.
    Erfle V; Goebel FD; Guzman CA; Le Grand R
    Microbes Infect; 2005 Nov; 7(14):1400-4. PubMed ID: 16243564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection.
    Locher CP; Witt SA; Ashlock BM; Polacino P; Hu SL; Shiboski S; Schmidt AM; Agy MB; Anderson DM; Staprans SI; zur Megede J; Levy JA
    Vaccine; 2004 Jun; 22(17-18):2261-72. PubMed ID: 15149785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
    Ensoli B; Cafaro A; Caputo A; Fiorelli V; Ensoli F; Gavioli R; Ferrantelli F; Cara A; Titti F; Magnani M
    Microbes Infect; 2005 Nov; 7(14):1392-9. PubMed ID: 16243561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
    Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.
    Catanzaro AT; Roederer M; Koup RA; Bailer RT; Enama ME; Nason MC; Martin JE; Rucker S; Andrews CA; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
    Vaccine; 2007 May; 25(20):4085-92. PubMed ID: 17391815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.